Table IV.

Effect of eculizumab on FACIT-Fatigue scores in patients with paroxysmal nocturnal haemoglobinuria.

	TRIUMPH			SHEPHERD
	Change from baseline median (mean ± SE)			Change from baseline median (mean ± SE)
	Week 26 placebo	Week 26 eculizumab	P-value	Week 52 eculizumab	P-value
Overall	−2·0 (−4·0 ± 1·71)	4·0 (6·4 ± 1·19)	<0·001	10·0 (12·2 ± 1·09)	<0·001
0 or 1 transfusion episodes during pretreatment year	–	–	–	11·0 (13·5 ± 2·13)	<0·001
Transfusion independent during study	–*	3·0 (7·0 ± 1·93)	<0·001	8·5 (12·9 ± 1·71)	<0·001
Receiving transfusion during study	−2·0 (−4·0 ± 1·71)	5·5 (5·7 ± 1·38)	<0·001	10·0 (11·5 ± 1·37)	<0·001

P-values are based on a signed rank test.

^*No placebo patients achieved transfusion independence.